Catalent, global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has signed an agreement for the acquisition of Juniper Pharmaceuticals.
Partnership
Through this acquisition, which includes the Nottingham-based Juniper Pharma Services division, Catalent’s formulation development, bioavailability solutions and clinical-scale oral dose manufacturing offerings will be strengthened and expanded.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented Jonathan Arnold, president of Catalent Oral Drug Delivery. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
The CRINONE (progesterone gel) franchise — currently marketed by Merck outside the US — will continue to be supported by Catalent. However, the company will not have further involvement in the development of Juniper’s Intravaginal Ring development pipeline — licensed to Daré Bioscience.